Non Small Cell Lung Cancer

Showing NaN - NaN of 45

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)

Not yet recruiting
  • Solid Tumor, Adult
  • +19 more
  • A2B694
  • xT CDx with HLA-LOH Assay
  • Duarte, California
  • +9 more
Sep 22, 2023

Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer Trial in United States (A2B530, xT-Onco with HLA-LOH Assay)

Not yet recruiting
  • Solid Tumor, Adult
  • +15 more
  • A2B530
  • xT-Onco with HLA-LOH Assay
  • Duarte, California
  • +6 more
Feb 10, 2023

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer Trial in United States (BMF-219)

Recruiting
  • Non Small Cell Lung Cancer
  • +16 more
  • Goodyear, Arizona
  • +10 more
Jan 24, 2023

Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer Trial in United States (device, drug, radiation, procedure)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Stage III Non-small-cell Lung Cancer
  • Durvalumab
  • +4 more
  • Chicago, Illinois
  • +3 more
Jan 18, 2023

Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose

Recruiting
  • Solid Tumor
  • +6 more
  • CM-24 and Nivolumab - Dose Escalation
  • +4 more
  • Scottsdale, Arizona
  • +10 more
Jan 17, 2023

Gastric Cancer, Renal Cell Carcinoma, Melanoma Trial in United States (HFB200301)

Recruiting
  • Gastric Cancer
  • +8 more
  • Scottsdale, Arizona
  • +9 more
Dec 22, 2022

Non Small Cell Lung Cancer, KRAS Activating Mutation Trial in Worldwide (VS-6766, VS-6766 and Defactinib)

Recruiting
  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation
  • avutometinib (VS-6766)
  • avutometinib (VS-6766) and Defactinib
  • Duarte, California
  • +44 more
Dec 22, 2022

Non Small Cell Lung Cancer Trial in Worldwide (Taletrectinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Beverly Hills, California
  • +58 more
Dec 13, 2022

Non Small Cell Lung Cancer Trial in United States (N-803 + Pembrolizumab, N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab,

Active, not recruiting
  • Non Small Cell Lung Cancer
  • N-803 + Pembrolizumab
  • +5 more
  • Anchorage, Alaska
  • +30 more
Nov 3, 2022

Tumors, Metastatic Cancer, Advanced Cancer Trial in United States (Niraparib, TSR-042, Carboplatin-Paclitaxel)

Active, not recruiting
  • Neoplasms
  • +6 more
  • Scottsdale, Arizona
  • +7 more
Oct 31, 2022

Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer Trial in San Francisco, Denver, San Antonio (P-MUC1C-ALLO1 CAR-T

Recruiting
  • Breast Cancer
  • +8 more
  • San Francisco, California
  • +4 more
Oct 26, 2022

Non Small Cell Lung Cancer Trial in Tampa, Houston (quaratusugene ozeplasmid, pembrolizumab, docetaxel)

Recruiting
  • Non Small Cell Lung Cancer
  • quaratusugene ozeplasmid
  • +3 more
  • Tampa, Florida
  • +2 more
Sep 12, 2022

Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (Selpercatinib)

Available
  • Non Small Cell Lung Cancer
  • +6 more
  • Goodyear, Arizona
  • +67 more
Aug 17, 2022

Mesothelioma, Glioblastoma, Renal Cell Carcinoma Trial in Korea, Republic of, Taiwan, United States (NGM707, NGM707 plus

Recruiting
  • Mesothelioma
  • +14 more
  • Los Angeles, California
  • +13 more
Aug 16, 2022

Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)

Recruiting
  • Advanced Solid Tumor
  • +18 more
  • PT199
  • Anti-PD-1 monoclonal antibody
  • Huntersville, North Carolina
  • +2 more
Aug 10, 2022

Solid Tumor, Adult, Head Neck Cancer, Non Small Cell Lung Cancer Trial in Worldwide (CX-2029)

Active, not recruiting
  • Solid Tumor, Adult
  • +4 more
  • Birmingham, Alabama
  • +24 more
Aug 5, 2022

Oncology, Solid Tumor, Non Small Cell Lung Cancer Trial in United States (MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution

Active, not recruiting
  • Oncology
  • +5 more
  • MRx0518
  • Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
  • Kansas City, Kansas
  • +4 more
Jul 5, 2022

Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)

Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +27 more
Jun 27, 2022

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)

Completed
  • Melanoma
  • +6 more
  • Combination of NKTR-214 + nivolumab
  • La Jolla, California
  • +57 more
Jun 22, 2022